Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Feng Chi Biotech Corp. (6744:TWSE), powered by AI.
Feng Chi Biotech Corp. is currently trading at $15.90. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Feng Chi Biotech Corp. on Alpha Lenz.
View Feng Chi Biotech Corp.'s valuation metrics on Alpha Lenz.
“Feng Chi Biotech Corp.'s ROE is 6.0%. Explore profitability and growth together.”
Ask for details →Feng Chi Biotech Corp. is a biotechnology company headquartered in Taipei, Taiwan, specializing in *genetic testing* and life science services. The firm offers a range of medical diagnostic solutions, including preimplantation genetic testing, prenatal genetic screening, newborn screening for heritable conditions, food and pharmaceutical microbiological testing, and medical translational research. It is also active in the distribution of advanced genetic testing technologies, particularly in the field of oncology, supporting precision medicine initiatives in areas such as colorectal and lung cancer. With a core focus on health technology, the company serves both healthcare providers and scientific researchers, playing a key role in public health, clinical diagnostics, and biomedical research sectors. Founded in 1992, Feng Chi Biotech Corp. supports healthcare innovation by delivering reliable diagnostic tools, thereby impacting disease prevention, early detection, and personalized treatment strategies in Taiwan’s growing healthcare market.
“Feng Chi Biotech Corp.'s ROE is 6.0%. Explore profitability and growth together.”
Ask for details →Feng Chi Biotech Corp. (ticker: 6744) is a company listed on TWSE in the Healthcare sector (Biotechnology). It has approximately 32 employees.
The current price is 15.9 with a P/E ratio of -x and P/B of -x.
ROE is 6.03% and operating margin is 7.81%. Annual revenue is $177M.